Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
997.4 INR | +0.95% | +3.96% | +44.72% |
Apr. 26 | Weak March Quarter Earnings Weigh Down Indian Equities on Friday | MT |
Apr. 26 | Zydus Lifesciences Gets US FDA's Final Approval for Generic Acne Cream | MT |
Sales 2024 * | 193B 2.31B | Sales 2025 * | 210B 2.52B | Capitalization | 994B 11.92B |
---|---|---|---|---|---|
Net income 2024 * | 35.8B 429M | Net income 2025 * | 37.34B 448M | EV / Sales 2024 * | 5.09 x |
Net cash position 2024 * | 13.47B 161M | Net cash position 2025 * | 33.33B 400M | EV / Sales 2025 * | 4.57 x |
P/E ratio 2024 * |
27.6
x | P/E ratio 2025 * |
26.5
x | Employees | 23,026 |
Yield 2024 * |
0.58% | Yield 2025 * |
0.59% | Free-Float | 24.87% |
Latest transcript on Zydus Lifesciences Limited
1 day | +0.95% | ||
1 week | +3.96% | ||
Current month | -0.99% | ||
1 month | -0.24% | ||
3 months | +31.95% | ||
6 months | +71.89% | ||
Current year | +44.72% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 44 | 97-07-31 | |
Director of Finance/CFO | - | - | |
Chairman | 71 | 95-05-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 72 | 18-12-05 | |
Chairman | 71 | 95-05-14 | |
Director/Board Member | 69 | 97-07-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.22% | 6 M€ | +6.07% | - | |
0.01% | 117 M€ | +1.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 997.4 | +0.95% | 1 408 142 |
24-05-02 | 988 | +3.61% | 2,760,717 |
24-04-30 | 953.6 | -0.99% | 1,728,594 |
24-04-29 | 963.1 | +1.66% | 1,094,730 |
24-04-26 | 947.4 | -0.40% | 697,528 |
Delayed Quote NSE India S.E., May 03, 2024 at 06:23 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+44.72% | 11.91B | |
+19.98% | 43.67B | |
+20.67% | 22.51B | |
+14.63% | 14.6B | |
+14.32% | 13.74B | |
-8.37% | 7.04B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+10.21% | 5.42B | |
-2.27% | 4.81B |
- Stock Market
- Equities
- ZYDUSLIFE Stock